Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

被引:472
作者
Burden, DA
Osheroff, N
机构
[1] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Med Oncol, Sch Med, Nashville, TN 37232 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1998年 / 1400卷 / 1-3期
关键词
anticancer drug; catalytic cycle; DNA cleavage complex; drug mechanism; topoisomerase II;
D O I
10.1016/S0167-4781(98)00132-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topoisomerase II is a ubiquitous enzyme that is essential for the survival of all eukaryotic organisms and plays critical roles in virtually every aspect of DNA metabolism. The enzyme unknots and untangles DNA by passing an intact helix through a transient double-stranded break that it generates in a separate helix. Beyond its physiological functions, topoisomerase II is the target for some of the most active and widely prescribed anticancer drugs currently utilized for the treatment of human cancers. These drugs act in an insidious fashion and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes that are normally fleeting intermediates in the catalytic cycle of the enzyme. Over the past several years, we have made considerable strides in our understanding of the catalytic mechanism of topoisomerase II and the mechanism of action of drugs targeted to this enzyme. These advances have provided novel insights into the physiological functions of topoisomerase II and have led to the development of more efficacious chemotherapeutic regimens and novel anticancer drugs. Considering the importance of topoisomerase II to the eukaryotic cell and to cancer chemotherapy, it is essential to understand its enzymatic function and pharmacological properties. Therefore, this review will discuss the mechanism of action of eukaryotic topoisomerase II and topoisomerase II-targeted drugs. 0167-4781/98/$ see front matter (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:139 / 154
页数:16
相关论文
共 166 条
  • [1] NUCLEOTIDE-BINDING TO THE 43-KILODALTON N-TERMINAL FRAGMENT OF THE DNA GYRASE-B PROTEIN
    ALI, JA
    ORPHANIDES, G
    MAXWELL, A
    [J]. BIOCHEMISTRY, 1995, 34 (30) : 9801 - 9808
  • [2] STRAND SPECIFICITY OF THE TOPOISOMERASE-II MEDIATED DOUBLE-STRANDED DNA CLEAVAGE REACTION
    ANDERSEN, AH
    CHRISTIANSEN, K
    ZECHIEDRICH, EL
    JENSEN, PS
    OSHEROFF, N
    WESTERGAARD, O
    [J]. BIOCHEMISTRY, 1989, 28 (15) : 6237 - 6244
  • [3] THE PRODUCTION OF CHROMOSOMAL ALTERATIONS IN HUMAN-LYMPHOCYTES BY DRUGS KNOWN TO INTERFERE WITH THE ACTIVITY OF DNA TOPOISOMERASE-II .1. M-AMSA
    ANDERSSON, HC
    KIHLMAN, BA
    [J]. CARCINOGENESIS, 1989, 10 (01) : 123 - 130
  • [4] [Anonymous], 1987, Molecular Biology of the Gene
  • [5] Z-DNA BINDING AND INHIBITION BY GTP OF DROSOPHILA TOPOISOMERASE-II
    ARNDTJOVIN, DJ
    UDVARDY, A
    GARNER, MM
    RITTER, S
    JOVIN, TM
    [J]. BIOCHEMISTRY, 1993, 32 (18) : 4862 - 4872
  • [6] NOVEL HELA TOPOISOMERASE-II IS THE II-BETA ISOFORM - COMPLETE CODING SEQUENCE AND HOMOLOGY WITH OTHER TYPE-II TOPOISOMERASES
    AUSTIN, CA
    SNG, JH
    PATEL, S
    FISHER, LM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1172 (03) : 283 - 291
  • [7] ILLEGITIMATE RECOMBINATION MEDIATED BY CALF THYMUS DNA TOPOISOMERASE-II INVITRO
    BAE, YS
    KAWASAKI, I
    IKEDA, H
    LIU, LF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (07) : 2076 - 2080
  • [8] BARNES S, 1995, J CELL BIOCHEM, P181
  • [9] HUMAN 170-KDA AND 180-KDA TOPOISOMERASES-II BIND PREFERENTIALLY TO CURVED AND LEFT-HANDED LINEAR DNA
    BECHERT, T
    DIEKMANN, S
    ARNDTJOVIN, DJ
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 1994, 12 (03) : 605 - 623
  • [10] BECK WT, 1993, ADV ENZYME REGUL, V33, P113